Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab

References

• National Psoriasis Foundation. Psoriasis.org. About psoriasis [online] [updated 2020 May 24; cited 2021 Jul]. Available from: https://www.psoriasis.org/about-psoriasis
   Google Scholar
• National Psoriasis Foundation. Psoriasis.org. About psoriatic arthritis [online] [updated 2020 Jan 15; cited 2021 Jul]. Available from: https://www.psoriasis.org/about-psoriatic-arthritis
   Google Scholar
• Ursin K, Lydersen S, Skomsvoll JF, et al. Disease activity during and after pregnancy in women with axial spondyloarthritis: a prospective multicenter study. Rheumatology. 2018;57(6):1064–1071.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Ltd. SANDIMMUN® soft gelatin capsules 25 mg, 50 mg, 100 mg (ciclosporin) summary of product characteristics; 2020 [cited 2021 Jul]. Available from: https://www.medicines.org.uk/emc/product/11090/smpc
   Google Scholar
• Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3(1):21–25.
   PubMedGoogle Scholar
• Mariette X, Flynn A, Förger F, et al. OP0017 lack of placental transfer of certolizumab pegol during pregnancy; results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study. Ann Rheum Dis. 2017;76:57–58.
   Web of Science ®Google Scholar
• Johansen CB, Jimenez-Solem E, Haerskjold A, et al. The use and safety of TNF inhibitors during pregnancy in women with psoriasis: a review. Int J Mol Sci. 2018;19(5):E1349.
   PubMed Web of Science ®Google Scholar
• Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing on controversies. Autoimmun Rev. 2020;19(1):102429.
   PubMed Web of Science ®Google Scholar
• Taltz (ixekizumab) injection, for subcutaneous use. Indianapolis (IN): Eli Lilly and Company; 2020 [cited 2021 Jul]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s020lbl.pdf
   Google Scholar
• Blegvad C, Skov L, Zachariae C. Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Expert Rev Clin Immunol. 2019;15(2):111–121.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology. 2020;59:3834–3844.
   PubMed Web of Science ®Google Scholar
• Yeung J, Gooderham MJ, Grewal P, et al. Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper. J Cutan Med Surg. 2020;24(1_suppl):3S–14S.
   PubMed Web of Science ®Google Scholar
• Soh MC, Moretto M. The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy. Obstet Med. 2020;13(1):5–13.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(9):1483–1490.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. UNCOVER-1 study group; UNCOVER-2 study group; UNCOVER-3 study group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour JP, et al. IXORA-S investigators. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORS-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, et al. IXORA-R study group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. Br J Dermatol. 2020;182(6):1348–1358.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control (U.S.), & Centers for Disease Control and Prevention (U.S.). Morbidity and mortality weekly report: MMWR. Atlanta (GA): U.S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control. Update on Overall Prevalence of Major Birth Defects – Atlanta, Georgia, 1978–2005; 2008 [cited 2021 Jul]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm
   Google Scholar
• Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349–364.
   PubMed Web of Science ®Google Scholar
• Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205–1207.
   PubMed Web of Science ®Google Scholar
• Geldhof A, Slater J, Clark M, et al. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf. 2020;43(2):147–161.
   PubMed Web of Science ®Google Scholar
• Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708–1712.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Crow JA, Ridley K, et al. Pregnancy outcomes in women with moderate to severe psoriasis: the PSOLAR experience. J Am Acad Dermatol. 2014;70:AB179.
   Web of Science ®Google Scholar
• Yurkon K, Guo CY, Harrison DD, et al. Pregnancy outcomes in women with dermatologic conditions exposed to infliximab. J Am Acad Dermatol. 2014;70:AB179.
   Web of Science ®Google Scholar